India Gene Therapy Market Size, Share & Forecast, By Therapy Type, Vector Type & Disease Area, 2026-2032

The India Gene Therapy Market was valued at USD 69 million in 2025 under the report's therapeutic-revenue scope. The estimate includes commercial gene-modified cellular therapies, qualifying one-time gene therapies delivered through Indian access pathways and directly attributable treatment revenue, while excluding standalone sequencing, diagnostics and non-genetically modified cell therapies. Commercialization strengthened after NexCAR19 and Qartemi created a domestic CAR-T revenue base. The market remains early-stage relative to mature pharmaceutical categories, but treatment economics are improving as local manufacturing and specialist hospital networks expand.

The market is projected to reach approximately USD 491 million by 2032, representing a 32.36% CAGR from the 2025 base. Growth is expected to accelerate as commercial CAR-T adoption expands, new hematologic indications reach market, domestic vector capacity strengthens and development programs move toward hemoglobinopathies and rare genetic diseases. Volume growth should initially exceed value growth because domestic manufacturing and process improvements reduce average treatment cost, but high-value in-vivo therapies can offset part of that price compression later in the forecast.

Profit pools should broaden from therapy intellectual property toward vector production, cell-processing systems, specialized hospitals, clinical logistics and patient financing. Autologous CAR-T requires patient-specific manufacturing and clinical coordination, giving integrated developers and treatment networks stronger economics than simple distributors. As manufacturing standardizes, some margin will move toward proprietary vectors, automation, release analytics and high-throughput treatment centres. In-vivo therapies may preserve higher per-patient values but depend on successful local access and reimbursement. This creates multiple investable layers beyond the therapy developer itself.

Affordability remains the largest near-term constraint, followed by manufacturing capacity and specialist-centre availability. Domestic CAR-T has reduced treatment prices materially versus international comparators, but advanced therapies remain expensive relative to mainstream Indian healthcare spending. Imported gene replacement products can carry multi-million-dollar global prices, making routine self-pay access unrealistic. Rare-disease policy infrastructure and specialist centres improve diagnosis and referral, but reimbursement mechanisms have not yet evolved sufficiently to support broad one-time curative therapy adoption at scale.

India is smaller by current value than China, Japan and Australia within the selected comparison group, but its modeled growth rate is higher. The strategic advantage is a combination of large patient populations, lower-cost domestic development and a rapidly expanding biotechnology ecosystem. China and Japan retain stronger current commercialization depth, while India is progressing from a lower base through indigenous CAR-T, rare-disease screening and advanced-manufacturing investments. This positions India as a growth market rather than a current regional revenue leader.

The expansion of genetically characterized patient populations is the most important long-term demand driver. India's sickle-cell program had completed more than 60.7 million screenings by July 2025 and identified approximately 215,000 affected individuals. This creates a defined population for future precision and potentially curative therapies, while oncology provides the nearer-term commercial base. As genetic screening, counselling and specialist referral improve, developers can identify eligible patients earlier and build more predictable treatment funnels for clinical trials and commercial launch planning.